10 Key ASCO 2014 Presentations in Lung Cancer
Exam Answers
Tuberculosis
Best of ASCO Metastatic Non-Small Cell Lung Cancer
Management of Drug-Resistant Tuberculosis Your name Institution/organization Meeting Date International Standard 15.
Management of Drug-Resistant Tuberculosis Your name Institution/organization Meeting Date International Standard 12.
Strategies to overcome resistance in NSCLC with driver mutations Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile Livorno-Italy.
Department of Thoracic/Head & Neck Medical Oncology Management of EGFR-Mutant NSCLC Resistant to EGFR-TKI therapy Anne S. Tsao, M.D. Associate Professor.
Acquired Resistance to EGFR TKIs: What Is It and How Do We Treat? Vincent A Miller, MD Thoracic Oncology Service Memorial Sloan-Kettering Cancer Center.
EGFR-Mutated Advanced NSCLC The Coming Paradigm Shift Faculty Suresh S. Ramalingam, MD Professor of Hematology/Oncology Director, Lung Cancer Program Winship.
Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) in Non-Small Cell Lung Cancer (NSCLC) Victor.
Department of Thoracic/Head & Neck
